

Funded vaccines for special groups from 1 July 2024

For specific eligibility details, please refer to individual vaccines on the [Pharmaceutical Schedule \(pharmac.govt.nz\)](https://www.pharmac.govt.nz)

For vaccine administration schedule, please refer to the online [Immunisation Handbook](#) or relevant IMAC factsheets (immune.org.nz/resources/factsheets)

**Zoster eligibility is very specific; please see Pharmaceutical Schedule for details.*

Adolescents and young people 13-25 years inclusively entering specified close-living situations	Meningococcal vaccines
Asplenia – functional or pre- or post-splenectomy (IMAC factsheet available)	Hib, influenza, meningococcal, pneumococcal and Tdap vaccines
Chemotherapy – following (IMAC factsheet available)	Hib, HPV, influenza, pneumococcal, Tdap and varicella vaccines
> Also consider immunosuppression for longer than 28 days	Hepatitis B and meningococcal vaccines
Cochlear implant	Hib, influenza and pneumococcal vaccines
Error of metabolism at risk of major metabolic decompensation	Influenza and varicella vaccines
Haematological malignancies	Zoster* vaccine
Haematopoietic stem cell transplantation (HSCT) – following (IMAC factsheet available)	Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, varicella and zoster* vaccines
> Also consider immunosuppression for longer than 28 days	Hepatitis B vaccine
Hepatitis A case – contact with	Hepatitis A vaccine
Hepatitis B case – contact with > Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive	Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth
> Household and sexual contacts of known acute hepatitis B cases or carriers	Hepatitis B vaccine
Hepatitis C positive	Hepatitis B vaccine
HIV positive	Hepatitis B, HPV, influenza, meningococcal, pneumococcal, varicella and zoster* vaccines
Immunosuppression > Household contacts of children or adults who will be/are immunosuppressed	Varicella vaccine
> Elective immunosuppression for longer than 28 days (IMAC factsheet available)	Varicella (prior to immunosuppression only), hepatitis B, Hib, influenza, meningococcal and Tdap vaccines
> Immunodeficiency	Primary: Hib, influenza, meningococcal, pneumococcal and zoster* vaccines Secondary: Influenza vaccine

Influenza Immunisation Programme • Pregnancy • Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant illness • Individuals aged 65 years or older • Individuals aged 6 months to under 65 years with an eligible medical condition	Influenza vaccine
Kidney disease (IMAC factsheet available)	Hepatitis, Hib, influenza, pneumococcal, Tdap, varicella and zoster* vaccines
Liver disease	Hepatitis A and varicella vaccines
Meningococcal disease case – contact with	Meningococcal vaccines
Needle stick injury – following	Hepatitis B vaccine
Non-consensual sexual intercourse – following	Hepatitis B vaccine
Neonatal Intensive Care Unit or Specialist Care Baby Unit admission more than 3 days	Tdap for parents/primary caregivers if maternal Tdap not given at least 14 days before birth
Pneumococcal disease – increased risk	Additional pneumococcal vaccines
Pregnancy (IMAC factsheet available)	Influenza and Tdap vaccines in every pregnancy
Solid organ transplantation (IMAC factsheet available)	Hepatitis A, hepatitis B, Hib, meningococcal, pneumococcal, Tdap, varicella and zoster* vaccines
> Prior to solid organ transplantation	
> Following solid organ transplantation	Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, Tdap and zoster* vaccines
Tuberculosis — infants and children aged under 5 years at risk of tuberculosis (TB) exposure	BCG vaccine

VACCINE KEY

BCG: tuberculosis; **Hib:** Haemophilus influenzae type b; **HPV:** human papillomavirus; **IPV:** inactivated polio vaccine; **Tdap:** tetanus, diphtheria, acellular pertussis.

Call 0800 IMMUNE (0800 466 863) for clinical advice

Funded vaccines for special groups from 1 July 2024

Vaccine	Individuals eligible for funded vaccine
<i>Haemophilus influenzae</i> type b (Hib vaccine)	An additional dose (as appropriate) for (re)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen longer than 28 days.
Hepatitis A vaccine	- One dose for close contacts of a hepatitis A case - Two doses for transplant patients; or children with chronic liver disease.
Hepatitis B vaccine or Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG)	- Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; children aged under 18 years who are considered not to have achieved a positive serology and require additional vaccination; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy; non-consensual sexual intercourse; or needle stick injury (20mcg/mL for infants, children and adults). - Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg from co-administration of two 20mcg/mL doses).
Herpes zoster vaccine UPDATED	Two doses for people 18 years of age or older with any of the following: pre- and post-haematopoietic stem cell transplant or cellular therapy; pre- or post-solid organ transplant; haematological malignancies; people living with poorly controlled HIV infection; planned or receiving disease modifying anti-rheumatic drugs (DMARDs – targeted synthetic, biologic, or conventional synthetic) for polymyalgia rheumatica, systemic lupus erythematosus or rheumatoid arthritis; end-stage kidney disease (CKD 4 or 5); primary immunodeficiency.
Human papillomavirus (HPV) vaccine	- Three doses for individuals aged 9-26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive - A maximum of four doses for people aged 9-26 years inclusively post-chemotherapy.
Influenza vaccine	- Pregnant women in every pregnancy during vaccination season - Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness - Individuals aged 65 years and older - Individuals aged 6 months to under 65 years with certain medical conditions, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation - Note: Eligibility is subject to change. Refer to the Pharmaceutical Schedule for any changes to funding criteria.
Meningococcal B vaccine	Aged 12 months or older - Up to two doses for individuals who have previously had meningococcal disease of any group or are a close contact of a meningococcal disease case of any group; post-haematopoietic stem cell transplantation; pre- and post-immunosuppression longer than 28 days; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive - One booster dose every five years for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional or anatomic asplenia; complement deficiency (acquired or inherited); or who are HIV-positive - Two doses for individuals aged 13-25 who are entering within the next three months, or in their first year of living in boarding school hostels, tertiary education halls of residence, military barracks, or prisons - Two doses for individuals who turn 13 years of age while living in boarding school hostels.

Meningococcal A, C, Y, W vaccine	Aged under 12 months Nimenrix is funded (maximum three doses dependent on age at first dose) for the following groups under the age of 12 months: - infants pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive - an infant who has previously had meningococcal disease of any group or who is a close contact of a meningococcal disease case of any group; post- post-haematopoietic stem cell transplantation; pre- and post-immunosuppression longer than 28 days. Aged 12 months or older - Up to three doses and a booster every five years for pre- and post-splenectomy; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive) - One dose for those who have previously had meningococcal disease of any group or who are a close contact of a meningococcal disease case of any group - A maximum of two doses for bone marrow transplant patients; or pre- and post-immunosuppression longer than 28 days - Adolescents and young adults aged 13-25 years inclusively, who are entering within the next three months, or are in their first year of living in a boarding school hostel, tertiary education halls of residence, military barrack, or prison - One dose for individuals who turn 13 years of age while living in boarding school hostels.
Pneumococcal conjugate (PCV13) vaccine	Infants and children aged under 5 years – up to four age-appropriate doses (see relevant factsheets) Children aged 12 months to under 18 years who have previously received two doses of PCV10 – up to two doses (as appropriate; see relevant factsheets) - Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2mg/kg per day or greater, or children who weigh more than 10kg on a total daily dosage of 20mg or greater; diabetes; Down syndrome; functional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre-or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure. Children aged 5 years or older, and adults – up to four age-appropriate dose (see relevant factsheets) - Pre- or post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive.
Pneumococcal polysaccharide (23PPV) vaccine	Children aged 2 years to under 18 years – up to two doses (as appropriate; see relevant factsheets) - Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2mg/kg per day or greater, or children who weigh more than 10kg on a total daily dosage of 20mg or greater; diabetes; Down syndrome; funtional asplenia; post-haematopoietic stem cell transplantation; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre-or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-solid organ transplantation; radiation therapy; or renal failure. Adults aged 18 years or older – up to three doses (as appropriate; see relevant factsheets) - Post-chemotherapy; post-haematopoietic stem cell transplantation; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive.
Tetanus, diphtheria and pertussis (Tdap) vaccine	One dose for pregnant women, in the second or third trimester of every pregnancy. One dose for parents or primary caregivers of infants admitted to a Neonatal Intensive Care Unit or Specialist Care Baby Unit for more than 3 days and whose mother did not receive maternal Tdap at least 14 days prior to birth. » Up to four additional doses (as appropriate) for (re)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post- splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen.

Tuberculosis BCG vaccine	Infants and children aged under 5 years • Living in a house or family with a person with current or past history of tuberculosis (TB), or • Having one or more household members or carers who within the last five years lived in a country with a rate of TB at 40/100,000 or greater for six months or longer, or • During their first five years will be living three months or longer in a country with a rate of TB 40/100,000 or greater.
Varicella vaccine - From age 12 months in primary care - From age 9 months in secondary/hospital care	Two doses for non-immune individuals: • Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist • Prior to elective immunosuppressive therapy that will be longer than 28 days • With chronic liver disease who may in future be candidates for transplantation • With deteriorating renal function before transplantation • Pre-solid organ transplantation • Post-chemotherapy; post-haematopoietic stem cell transplantation, on the advice of their specialist • Who are immune competent inpatients exposed to varicella, for post-exposure prophylaxis. Two doses for individuals with no clinical history of varicella infection or immunisation: • With an inborn error of metabolism at risk of major metabolic decompensation • Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation. • Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation.

Call 0800 IMMUNE (0800 466 863) for clinical advice